Sectors
TNYA
Tenaya Therapeutics, Inc.
0.74
4 x 0.73
21 x 0.75
bid
ask
+
0.01
0.79%
09:41 AM
timesize
| Ytd | 4.38% | |
| 1y | 9.13% |
0.74
day range
0.76
0.53
52 week range
2.35
| Open | 0.75 | Prev Close | 0.74 | Low | 0.74 | High | 0.76 | Mkt Cap | 161.27M |
| Vol | 118.28K | Avg Vol | 2.92M | EPS | -0.47 | P/E | -1.58 | Forward P/E | -1.28 |
| Beta | 2.83 | Short Ratio | 2.31 | Inst. Own | 73.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 0.77 | 200-d Avg | 0.87 | 1yr Est | 18.50 |
| Income Statement | |||
| Total Revenue | 1.11M | ||
| Revenues (USD) | 1.11M | ||
| Gross Profit | 1.11M | ||
| Operating Expenses | 45.20M | ||
| Research and Development Expense | 16.60M | ||
| Selling, General and Administrative Expense | 5.41M | ||
| Operating Income | -44.09M | ||
| Net Income | -43.39M | ||
| Net Income Common Stock | -43.39M | ||
| Net Income Common Stock (USD) | -43.39M | ||
| Consolidated Income | -43.39M | ||
| Earnings per Basic Share | -0.20 | ||
| Earnings per Basic Share (USD) | -0.20 | ||
| Earnings per Diluted Share | -0.20 | ||
| Earning Before Interest & Taxes (EBIT) | -43.39M | ||
| Earning Before Interest & Taxes (USD) | -43.39M | ||
| Weighted Average Shares | 217.57M | ||
| Weighted Average Shares Diluted | 217.57M | ||
| Balance Sheet | |||
| Cash and Equivalents | 78.08M | ||
| Cash and Equivalents (USD) | 78.08M | ||
| Trade and Non-Trade Receivables | 371.00K | ||
| Current Assets | 86.01M | ||
| Property, Plant & Equipment Net | 5.46M | ||
| Total Assets | 93.54M | ||
| Debt Current | 2.88M | ||
| Total Debt | 3.95M | ||
| Current Liabilities | 19.02M | ||
| Debt Non-Current | 1.07M | ||
| Total Liabilities | 24.13M | ||
| Accumulated Retained Earnings (Deficit) | -667.67M | ||
| Shareholders Equity | 69.41M | ||
| Shareholders Equity (USD) | 69.41M | ||
| Assets Non-Current | 7.53M | ||
| Total Debt (USD) | 3.95M | ||
| Deferred Revenue | 9.66M | ||
| Liabilities Non-Current | 5.11M | ||
| Trade and Non-Trade Payables | 2.90M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.37M | ||
| Net Cash Flow from Financing | 909.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -2.80M | ||
| Capital Expenditure | -159.00K | ||
| Issuance (Purchase) of Equity Shares | 909.00K | ||
| Net Cash Flow from Investing | -159.00K | ||
| Net Cash Flow from Operations | -3.55M | ||
| Share Based Compensation | 1.70M | ||